Paget's disease of the breast differential diagnosis: Difference between revisions
Preeti Singh (talk | contribs) No edit summary |
Preeti Singh (talk | contribs) No edit summary |
||
Line 26: | Line 26: | ||
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Benign or Malignant | ! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Benign or Malignant | ||
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Etiology | ! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Etiology | ||
! colspan=" | ! colspan="8" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Clinical manifestations | ||
! colspan="2" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para-clinical findings | ! colspan="2" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para-clinical findings | ||
| rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold Standard | | rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold Standard | ||
| rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Associated factors''' | | rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Associated factors''' | ||
|- | |- | ||
! colspan=" | ! colspan="6" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Symptoms | ||
! colspan="2" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical examination | ! colspan="2" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical examination | ||
|- | |- | ||
Line 40: | Line 40: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Nipple Discharge | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Nipple Discharge | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Erythema | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Erythema | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Involved areas | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Involved areas | ||
Line 56: | Line 54: | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" | – | | align="center" style="background:#F5F5F5;" | – | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
Line 86: | Line 83: | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | – | | align="center" style="background:#F5F5F5;" | – | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 127: | Line 123: | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" |– | | align="center" style="background:#F5F5F5;" |– | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" | Surrounding the area in contact with the offending agent | | align="center" style="background:#F5F5F5;" | Surrounding the area in contact with the offending agent | ||
Line 154: | Line 149: | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 180: | Line 174: | ||
|- | |- | ||
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Melanoma|Malignant melanoma]] | ! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Melanoma|Malignant melanoma]] | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 200: | Line 193: | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Erythematous | |||
* Skin colored | |||
* Patch | |||
* Plaque | |||
* scaly | |||
* variable size | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Fair-skinned individuals: sun-exposed areas | |||
* In black individuals: legs, anus, and areas of chronic inflammation | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 209: | Line 212: | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Keratinocytic dysplasia of the epidermis | |||
* No infiltration into dermis | |||
* Pleomorphic keratinocytes | |||
* Hyperchromatic nuclei | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 217: | Line 224: | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Erythematous | |||
* Superficial scaly patch | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Sun-exposed areas | |||
* Head (cheek and nose) | |||
* Trunk | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Superficial fine telangiectasia | |||
* Shiny white to red, translucent or opaque structureless areas | |||
* Multiple small erosions | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Large, hyperchromatic, oval nuclei | |||
* Minimal cytoplasm | |||
* Small basaloid nodules | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
|- | |- | ||
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Basal cell carcinoma|Pagetoid basal cell carcinoma]] | ! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Basal cell carcinoma|Pagetoid basal cell carcinoma]] | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 248: | Line 264: | ||
|- | |- | ||
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Intraductal papilloma|Benign intraductal papilloma]] | ! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Intraductal papilloma|Benign intraductal papilloma]] | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 265: | Line 280: | ||
|- | |- | ||
! style="background: #DCDCDC; padding: 5px; text-align: center;" |Pagetoid dyskeratosis | ! style="background: #DCDCDC; padding: 5px; text-align: center;" |Pagetoid dyskeratosis | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 285: | Line 299: | ||
| align="center" style="background:#F5F5F5;" |* Common among [[perimenopausal]]<nowiki/>women | | align="center" style="background:#F5F5F5;" |* Common among [[perimenopausal]]<nowiki/>women | ||
* Usually resolve spontaneously | * Usually resolve spontaneously | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 302: | Line 315: | ||
|- | |- | ||
! style="background: #DCDCDC; padding: 5px; text-align: center;" |Nipple duct adenoma | ! style="background: #DCDCDC; padding: 5px; text-align: center;" |Nipple duct adenoma | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 319: | Line 331: | ||
|- | |- | ||
! style="background: #DCDCDC; padding: 5px; text-align: center;" |Benign Toker cell hyperplasia | ! style="background: #DCDCDC; padding: 5px; text-align: center;" |Benign Toker cell hyperplasia | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 337: | Line 348: | ||
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Breast abscess]] | ! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Breast abscess]] | ||
| align="center" style="background:#F5F5F5;" |Benign | | align="center" style="background:#F5F5F5;" |Benign | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 357: | Line 367: | ||
|- | |- | ||
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Mondors disease]] | ! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Mondors disease]] | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 377: | Line 386: | ||
* [[Benign]] | * [[Benign]] | ||
* No increased risk of [[malignancy]] | * No increased risk of [[malignancy]] | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 401: | Line 409: | ||
|- | |- | ||
! style="background: #DCDCDC; padding: 5px; text-align: center;" |Inflammatory Breast Cancer | ! style="background: #DCDCDC; padding: 5px; text-align: center;" |Inflammatory Breast Cancer | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | |
Revision as of 17:03, 21 February 2019
Paget's disease of the breast Microchapters |
Differentiating Paget's disease of the breast from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Paget's disease of the breast differential diagnosis On the Web |
American Roentgen Ray Society Images of Paget's disease of the breast differential diagnosis |
Paget's disease of the breast differential diagnosis in the news |
Blogs on Paget's disease of the breast differential diagnosis |
Directions to Hospitals Treating Paget's disease of the breast |
Risk calculators and risk factors for Paget's disease of the breast differential diagnosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Suveenkrishna Pothuru, M.B,B.S. [2]
Overview
Paget's disease of the breast must be differentiated from atopic dermatitis, eczema, psoriasis, malignant melanoma, Bowen's disease, basal cell carcinoma, and pagetoid dyskeratosis.[1][2]
Differential Diagnosis
Paget’s disease of the breast must be differentiated from other benign and malignant processes of nipple-areola complex such as:[1][2]
- Atopic dermatitis
- Chronic contact dermatitis
- Lactiferous duct ectasia
- Chronic eczema
- Psoriasis
- Nipple duct adenoma
- Malignant melanoma
- Bowen’s disease
- Superficial basal cell carcinoma
- Pagetoid basal cell carcinoma
- Benign intraductal papilloma
- Pagetoid dyskeratosis
Category | Diseases | Benign or Malignant | Etiology | Clinical manifestations | Para-clinical findings | Gold Standard | Associated factors | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Symptoms | Physical examination | ||||||||||||||
Lab Findings | Histopathology | ||||||||||||||
Rash | Nipple Discharge | Erythema | Involved areas | Mastalgia | Breast Exam | Other | Serum IgE | ||||||||
Eczema | Scalp, face, trunk, postauricular, diaper area and axilla | + | – | + |
|
Nl |
|
Risk factors include
Generalized seborrheic erythroderma in immunodeficient patients |
|||||||
Skin disorders | Atopic dermatitis | Benign |
|
– | + |
|
– |
|
↑ |
|
| ||||
Allergic contact dermatitis[3] | Benign |
|
Erythematous well-demarcated papules | – | + | Surrounding the area in contact with the offending agent | + |
|
Nl |
|
| ||||
Psoriasis | Benign |
|
Well-circumscribed, pink papules and symmetrically distributed cutaneous plaques with silvery scales | + | + |
|
+ |
|
Nl |
|
Risk factors include
| ||||
Malignant melanoma | |||||||||||||||
Bowen’s disease |
|
|
|
||||||||||||
Superficial basal cell carcinoma |
|
|
|
|
|||||||||||
Pagetoid basal cell carcinoma | |||||||||||||||
Benign intraductal papilloma | |||||||||||||||
Pagetoid dyskeratosis | |||||||||||||||
Lactiferous duct ectasia | Benign | * Common among perimenopausalwomen
|
* Distention of subareolar ducts | Ultrasound:
|
|||||||||||
Nipple duct adenoma | |||||||||||||||
Benign Toker cell hyperplasia | |||||||||||||||
Breast abscess | Benign | + |
|
|
|||||||||||
Mondors disease | |||||||||||||||
Mastitis |
|
+ | ± |
|
|
||||||||||
Inflammatory Breast Cancer |
References
- ↑ 1.0 1.1 Gaspari, Eleonora; Ricci, Aurora; Liberto, Valeria; Scarano, Angela Lia; Fornari, Maria; Simonetti, Giovanni (2013). "An Unusual Case of Mammary Paget's Disease Diagnosed Using Dynamic Contrast-Enhanced MRI". Case Reports in Radiology. 2013: 1–5. doi:10.1155/2013/206235. ISSN 2090-6862.
- ↑ 2.0 2.1 Lopes Filho, Lauro Lourival; Lopes, Ione Maria Ribeiro Soares; Lopes, Lauro Rodolpho Soares; Enokihara, Milvia M. S. S.; Michalany, Alexandre Osores; Matsunaga, Nobuo (2015). "Mammary and extramammary Paget's disease". Anais Brasileiros de Dermatologia. 90 (2): 225–231. doi:10.1590/abd1806-4841.20153189. ISSN 1806-4841.
- ↑ Nosbaum A, Vocanson M, Rozieres A, Hennino A, Nicolas JF (2009). "Allergic and irritant contact dermatitis". Eur J Dermatol. 19 (4): 325–32. doi:10.1684/ejd.2009.0686. PMID 19447733.